Back to Search
Start Over
FosA3 emerging in clinical carbapenemase-producing C. freundii.
- Source :
- Frontiers in Cellular & Infection Microbiology; 2024, p1-8, 8p
- Publication Year :
- 2024
-
Abstract
- Fosfomycin (FOS) is an effective antibiotic against multidrug-resistant Enterobacterales, but its effectiveness is reducing. Little is known on the current prevalence of FosA enzymes in low-risk pathogens, such as Citrobacter freundii. The aim of the study was the molecular characterization of a carbapenemase- and FosA-producing C. freundii collected in Italy. AK867, collected in 2023, showed an XDR profile, retaining susceptibility only to colistin. AK867 showed a FOS MIC >128 mg/L by ADM. Based on WGS, AK867 belonged to ST116 and owned a wide resistome, including fosA3, blaKPC-2, and blaVIM-1. fosA3 was carried by a conjugative pKPC-CAV1312 plasmid of 320,480 bp, on a novel composite transposon (12,907 bp). FosA3 transposon shared similarities with other fosA3-harboring pKPC-CAV1312 plasmids among Citrobacter spp. We report the first case of FosA3 production in clinical carbapenemase-producing C. freundii ST116. The incidence of FosA3 enzymes is increasing among Enterobacterales, affecting even low-virulence pathogens, as C. freundii. [ABSTRACT FROM AUTHOR]
- Subjects :
- CITROBACTER freundii
FOSFOMYCIN
CITROBACTER
PLASMIDS
COLISTIN
Subjects
Details
- Language :
- English
- ISSN :
- 22352988
- Database :
- Complementary Index
- Journal :
- Frontiers in Cellular & Infection Microbiology
- Publication Type :
- Academic Journal
- Accession number :
- 179523461
- Full Text :
- https://doi.org/10.3389/fcimb.2024.1447933